JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
88 hedge funds and large institutions have $125M invested in Jounce Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 20 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
less funds holding
Funds holding: →
38% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 26
43% less capital invested
Capital invested by funds: $221M → $125M (-$95.1M)
Holders
88
Holding in Top 10
2
Calls
$448K
Puts
$216K
Top Buyers
| 1 | +$2.96M | |
| 2 | +$1.38M | |
| 3 | +$1.34M | |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.32M |
| 5 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$1.12M |
Top Sellers
| 1 | -$3.21M | |
| 2 | -$1.76M | |
| 3 | -$1.75M | |
| 4 |
Two Sigma Investments
New York
|
-$1.08M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.03M |